$180.00
High-purity for laboratory research. This first-in-class dual incretin receptor agonist (GIP/GLP-1) is a potent tool for studying metabolic pathways and insulinotropic polypeptide receptors.
Tirzepatide is a first‑in‑class dual incretin receptor agonist that activates both the glucose‑dependent insulinotropic polypeptide receptor (GIPR) and the glucagon‑like peptide‑1 receptor (GLP‑1R). This “twincretin” mechanism produces synergistic metabolic effects that surpass those of GLP‑1–only agonists.
Tirzepatide is a first‑in‑class dual incretin receptor agonist that activates both the glucose‑dependent insulinotropic polypeptide receptor (GIPR) and the glucagon‑like peptide‑1 receptor (GLP‑1R). This “twincretin” mechanism produces synergistic metabolic effects that surpass those of GLP‑1–only agonists.
